*06/2017*

# New Analogs of Barbadin as Perspective Inhibitors of the ß-Arrestin/ß2-Adaptin Interaction

A recent paper from *Nature Communications** showed that authors, using a combination of virtual screening and cell-based assays, identified a small molecule (**Barbadin**) that selectively inhibits the interaction between beta-arrestin and the beta2-adaptin subunit of the clathrin adaptor protein AP2 without interfering with the formation of receptor/beta-arrestin complexes.

**Barbadin** was acquired from our company, OTAVA, and currently, we are offering all three the most active published compounds and twenty-three analogs. All of them are available from our company and are in stock:




Barbadin
OTV#: 0129720278




Analogue-A
OTV#: 0125228771




Cpd #43
OTV#: 7211730697

**As an additional service, we offer about 1,000 new analogs of Barbadin which could be exclusively synthesized upon request.**

** A new inhibitor of the beta-arrestin/AP2 endocytic complex reveals interplay between GPCR internalization and signalling, Nature Communications 8, Article number: 15054 (2017) (DOI: 10.1038/ncomms15054).*

---

Feel free to contact me if you need more information.
I am looking forward to your reply.

Best regards,
Andriy Dmytrenko, PhD, MBA
Director of Business Development and Marketing

OTAVA
Tel.: 1-416-549-8030
Fax: 1-866-881-9921 (Toll-free in US & Canada)
info@otavachemicals.com
north.america@otavachemicals.com